Nykode Reports Interim Results of VB10.16 in P-II (VB C-02) Trial for the Treatment of Advanced Cervical Cancer
Shots:
- The P-II (VB C-02) trial evaluates VB10.16 + atezolizumab vs atezolizumab alone in 52 patients with advanced or recurrent, non-resectable HPV16+ cervical cancer. The updated efficacy data is expected in H1’23
- The results from 39 patients with a median follow-up of 6mos. showed ORR (21%) including 2 CRs & 6 PRs, high DCR (64%), anti-tumor activity in PD-L1+ & -ve patients (ORR of 27% & 17%; DCR of 77% & 58%) & clinical benefit in PD-L1-ve population
- DCR (71%) in patients with non-inflamed tumors with a differentiated anti-tumor response, was safe & well tolerated, 10% has grade ≥3 TRAEs with no increased toxicity, favorable safety profile consistent with prior results for Nykode DNA vaccine technology platform
Ref: Globenewswire | Image: Nykode
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
